Navigation Links
Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year
Date:2/26/2009

LITTLETON, Mass., Feb. 26 /PRNewswire/ -- Still River Systems announced today the successful operation of the world's highest field, high energy cyclotron magnet. Still River's magnet is the key technical element for reducing the size and cost of the particle accelerator that will deliver proton therapy at a number of hospitals beginning with the first installation at Barnes Jewish Hospital in St. Louis, Missouri this fall.

"The last six months have been very exciting," said Marc Buntaine, CEO. "Still River has achieved all of the component milestones that bring us to system integration and delivery." Proton therapy, widely regarded as the next evolutionary step in the radiation treatment of cancer, has seen unprecedented interest from the radiation oncology and patient communities in recent years. However, the large size and high cost of existing proton therapy systems have made it difficult for the average hospital to add this powerful tool to their cancer fighting arsenal.

The heart of the Monarch250, a superconducting magnet developed in an industrial and academic partnership with the Massachusetts Institute of Technology, has now tested operational and stable at its full design current "This magnet sets a record for magnetic field strength used in a high energy cyclotron. The cyclotron built around this magnet will be the most compact source for proton therapy available today." said Dr. Kenneth Gall, founder and Chief Technology Officer. "All of the Monarch250 sub-systems are now in the final phases of manufacturing and will be ready to ship to our first customers for installation later this year".

Still River's Monarch250 proton therapy system, a unique and compact machine, was developed to provide proton therapy at a greatly reduced cost and size. In addition, Still River Systems has incorporated the latest advancements in radiation therapy patient management with its innovative accelerator technology, including a robotic couch for patient positioning, dedicated proton therapy treatment planning, cone beam CT imaging, and motion management. All of these clinical systems have been integrated within the Monarch250 platform. "Our goal is to provide our customers with a fully integrated, turnkey proton therapy solution with the most advanced clinical systems for patient management" said Dr. Skip Rosenthal, Vice President of Clinical Systems. "Integrating these key radiation therapy technologies is critical to ease of use in a clinical setting."

Still River Systems first installation sites, Barnes Jewish Hospital in St. Louis, Missouri and Robert Wood Johnson University Hospital in New Jersey, have begun construction for the new facilities that will house the first Monarch250 systems in the United States.

Still River Systems, based in Littleton, Massachusetts, is dedicated to providing physicians and their patients' access to high quality, cost-effective proton therapy solutions. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment. This system has not yet been cleared by the FDA for commercial use in clinical therapy. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit www.StillRiverSystems.com.


'/>"/>
SOURCE Still River Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
2. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
3. Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment
4. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
5. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
6. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
9. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
10. Stem Cell Regeneration Repairs Congenital Heart Defect
11. TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):